The glucosylceramide synthase inhibitor PDMP causes lyso-somal lipid accumulation and mTOR inactivation
Ontology highlight
ABSTRACT: We investigated subcellular sphingolipid distribution using a functionalized sphingosine analogue (pacSph) by confocal microscopy in control, PDMP and NB-DNJ (Miglustat) treated WT and SGPL1 knock-out cells (experimentA; channel 1: pacSph, channel 2: Lamp1). We studied lysosomal sphingolipid (pacSph) export using pulse-chase experiments in control and PDMP treated SGPL1 knock-out cells (experimentB; channel 1: pacSph, channel 2: Lamp1). We analyzed other lipids such as LBPA (immunofluorescence staining) and cholesterol (filipin staining) at the lysosome in control, PDMP and NB-DNJ (Miglustat) treated WT cells by microscopy (experimentC). We investigated a timeline of lipid accumulating effects arising from PDMP treatment by confocal microscopy. Therefore, we investigated LBPA (immunofluore
ORGANISM(S): Homo sapiens (human)
SUBMITTER: Pia Hartwig
PROVIDER: S-BIAD144 | bioimages |
REPOSITORIES: bioimages
ACCESS DATA